European Congress of Endocrinology 2010
Prague, Czech Republic
24 April 2010 - 28 April 2010
European Society of Endocrinology
Cushing's syndrome: screening and diagnosis aspects
1Clinic of Endocrinology, University of Medicine and Pharmacy ‘Victor Babeş’, Timisoara, Romania; 2Student in the VIth year, University of Medicine and Pharmacy ‘Victor Babeş’, Timisoara, Romania; 3Clinic of Metabolic Diseases, County Hospital No. 1, Timisoara, Romania; 4Institute of Cardiology, Timisoara, Romania; 5Clinic of Nephrology, County Hospital No. 1, Timisoara, Romania.
The diagnosis of Cushing’s syndrome, in the clinical practice, requires investigations necessary for distinguishing it from obesity with reactive hypercorticism and for differentiating its forms.
The study group was represented by 85 cases of hypercorticism (hospitalized in the Clinic of Endocrinology Timisoara during the period 2000–2009) divided in two groups: obesity with reactive hypercorticism (81.18%) respectively, Cushing’s syndrome with its forms (18.82%).
The medical history accompanied by the clinical examination is very important in revealing the clinical features of Cushing’s syndrome. Loss of circadian rhythm of cortisol is a sensitive screening test. The assessment of the basal plasma cortisol levels, in the study group, showed significant higher levels (P<0.01) in patients with Cushing’s syndrome in comparison to obesity with reactive hypercorticism. Low-dose (1–2 mg) overnight dexamethasone suppression tests are useful for Cushing’s syndrome screening (it was observed that there was no cortisol suppression in patients with Cushing’s syndrome in comparison to those with obesity with reactive hypercorticism (P<0.00001)); while, high-dose (8 mg) dexamethasone suppression tests helps in differentiating some Cushing’s syndrome forms (a lowering in the cortisol level over 50%, in patients with Cushing’s disease and no response in cases with Cushing’s syndrome caused by an adrenal adenoma/carcinoma – P<0.01).
The patients with Cushing’s syndrome also presented a significant decreased values of the serum TSH (P<0.0001), FT4 (P<0.00001), FSH (P<0.01) and LH (P<0.00001) versus those with obesity.
Endocrine Abstracts (2010) 22 P10